Lord, Abbett & Co
ORIC icon

Lord, Abbett & Co’s Oric Pharmaceuticals ORIC Stock Holding History

Lord, Abbett & Co’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-542,598
Closed -$6.88M – 613
2026
Q1 		$6.88M Sell
542,598
-21,655
-4% -$246K 0.02% 409
2025
Q4 		$4.62M Buy
+564,253
New +$6.5M 0.01% 474

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Lord, Abbett & Co's ORIC Position: Q2 2026 in Review

Lord, Abbett & Co sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 542,598 shares — an estimated $6.88M sold.

Lord, Abbett & Co first reported a position in ORIC in Q4 2025 and held it in 2 quarters. The position peaked at $6.88M in Q1 2026. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Lord, Abbett & Co reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Lord, Abbett & Co sold 542,598 Oric Pharmaceuticals shares in Q2 2026, an estimated $6.88M.
  • Lord, Abbett & Co first reported a position in Oric Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Lord, Abbett & Co's Oric Pharmaceuticals position peaked at $6.88M in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.